Retatrutide

Retatrutide is a synthetic triple agonist metabolic peptide investigated in late-stage clinical research for its activity at glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. Phase 3 clinical trials have evaluated Retatrutide as a coordinated multi-receptor signaling molecule influencing incretin and glucagon pathway activity associated with glucose regulation, lipid metabolism, and systemic energy balance under controlled clinical conditions. Its tri-receptor engagement distinguishes it in metabolic research models examining integrated endocrine and energy-partitioning responses.

In publicly released Phase 3 data from the TRIUMPH clinical program, once-weekly administration over 68 weeks demonstrated mean body-weight reductions of up to approximately 28.7% at the highest evaluated dose, compared with approximately 2% in placebo cohorts. Dose-dependent responses were observed across treatment groups, with substantial proportions of participants achieving ≥25%, ≥30%, and ≥35% body-weight reduction thresholds. Reported outcomes also included improvements in cardiometabolic markers such as fasting glucose, HbA1c, lipid parameters, and blood-pressure measures.